Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Key claim: BEBT-507 is entering a multicenter open-label Phase I (Ia dose-escalation then Ib dose-expansion) trial to assess safety, tolerability, PK, pharmacodynamics, and preliminary efficacy in polycythemia vera and to select a Phase III dose.
Abstract
This is a multicenter, open-label Phase I clinical trial of BEBT-507 in subjects with polycythemia vera(PV). Phase Ia is a single-agent dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of BEBT-507 in subjects with PV . Based on the results of Phase Ia, two doses will be selected for further evaluation in Phase Ib to assess the efficacy, safety, and PK profile of BEBT-507 in subjects with PV , and to recommend a dose for Phase III clinical trials.
Why this matters
BEBT-507 is one of a growing set of investigational agents entering formal clinical development for polycythemia vera, a space historically dominated by hydroxyurea, ropeginterferon, and ruxolitinib. A first-in-PV Phase I with dose-escalation/expansion sets the stage for eventual comparative positioning against these standards, though at this stage only the trial design — not efficacy or mechanism — is on record.